1. Introduction {#sec0005}
===============

Alzheimer\'s disease (AD) is a chronic and progressive neurodegenerative disorder, characterized by memory impairment, cognitive dysfunction, and behavioral disturbances along with central cholinergic function loss ([@bib0005]). AD has been found to be associated with cholinergic deficit and is characterized by significant decrease in acetylcholine (ACh) amount ([@bib0015]). ACh is a neurotransmitter, its neurotransmitter action diminish by cleaving ([@bib0095]) or inhibiting mainly by acetylcholinesterase (AChE) and BuChE, considered to be important in the pathology of AD ([@bib0050]). Both enzymes present in the brain, as AChE is mostly located in neurons and BuChE is largely associated with glial cell ([@bib0120]). Normally, in the healthy brain, AChE accounts for 80% while BuChE accounts for remaining 20% role in regulating the brain cholinesterase (ChE) activity and also evidently play a role in AD pathology and disease progression. However, in AD patient's brain, AChE activity may be reduced to 55--67% while BuChE activity increases and BuChE is accumulated in neurons, glial cells, neurotic plaques and tangles ([@bib0045]; [@bib0090]). The most effective accepted treatment strategy against AD is the elevation of ACh amount through AChE enzyme inhibition ([@bib0010]). Therefore, AChE and BuChE inhibitors have become notable in the treatment of AD. However, the several present AChE inhibitors (rivastigmine, donepezil and tacrine) use for the treatment of AD possess some side effects, and secondly, effective only against mild type of AD and no BuChE inhibitors available to present ([@bib0105]). A few BuChE inhibitors have been discovered, but still need to develop new drugs to treat AD effectively.

The ChE inhibitors specifically act on the enzymes that hydrolyze the ACh during synaptic release. The use of agents with enhanced selectivity for BuChE including cymserine and MF-8622 indicate potential therapeutic benefit of inhibiting BuChE in AD and related dementias. BuChE specific inhibition is unlikely to be associated with adverse events and may show efficacy without remarkable side effects ([@bib0040]; [@bib0115]). Therefore, BuChE may be considered as an important target for novel drug development to treat AD. Henceforth, the development of specific BuChE inhibitors and continues use of ChE inhibitors may lead to improved clinical outcomes ([@bib0040]).

This paper describes the synthesis and BuChE inhibitory activity of novel anthrarobin acyl derivatives (**3**--**5**, 7--**8**) while compounds **2** and **6** have been reported for their antioxidant potential by the same group ([@bib0065]). Anthrarobin is a substituted polycyclic hydrocarbon and its derivatives have shown diverse activity depending on the nature of attach functional groups. Naturally isolated and synthetic anthrarobin derivatives are found to be active against 5-alpha (α) reductase, which is involved in production of benign prostatic hyperplastic and prostatic cancer ([@bib0115]). Anthrarobin (anthracene-1,2,10-triol) is also found to have xanthine oxidase inhibitory activity at 68.35 μM concentration ([@bib0110]). Any minute change in the existing structure of anthrarobin may reveal different biological activities and various pharmacological effects ([@bib0035]; [@bib0055]). Due to the potent and diverse activities of anthrarobin derivatives, this study was planned to synthesize and determine the BuChE inhibition activity of new anthrarobin derivatives. Furthermore, docking studies were also performed to understand interactions between ligand showing potent inhibitory activity and receptor.

2. Experimental {#sec0010}
===============

2.1. Material and methods {#sec0015}
-------------------------

All the chemicals and solvents were purchase from Sigma and used as such. Thin layer chromatography (TLC) was performed on precoated 0.5 mm thick silica gel 60 F~254~ aluminum sheets. TLC plates were sprayed with 5% (v/v) aqueous solution of H~2~SO~4~, containing 4% (w/v) phosphomolybdic acid, 0.5% (w/v) ceric ammonium sulfate, and heated at 120 °C to visualize the spots. IR spectra were recorded on Shimadzu FTIR-8900 spectrometer (Shimadzu, Kyoto, Japan) as KBr pellets. ^1^H NMR spectra were recorded on a Bruker AM-400 instrument (Bruker, Faellanden, Switzerland) in CDCl~3~ solvent with tetramethylsilane as an internal standard. The chemical shifts are reported in ppm (*δ*) and coupling constant (*J*) are given in Hz. Mass spectra were obtained in an electron impact mode on Finnigan MAT-112 and MAT-113 spectrometers and ions are given in *m/z* (%).

2.2. General synthetic procedure of anthrarobin acyl derivatives (2--8) {#sec0020}
-----------------------------------------------------------------------

An acetic anhydride or acyl chloride (1--3 ml) was added to a pyridine (2 ml) solution of anthrarobin (**1**; 100 mg, for each reaction), and the reaction mixture shortly warmed and left for overnight at room temperature. The mixture was then poured over crushed ice and extracted with ethyl acetate (AcOEt). The AcOEt layer was washed with water, dried over anhydrous Na~2~SO~4~ and evaporated under reduced pressure to the product residue. The purity of the products was checked through TLC.

### 2.2.1. 1,10-Dihydroxyanthracene-2-acetate (2) {#sec0025}

White powder; Yield: 23%; IR (KBr) ν~max~ cm^−1^:3490 (OH), 1765 (ester), 1602--1415 (aromatic moieties), 1310 (O-C); ^1^H NMR (CDCl~3~, 400 MHz): *δ* = 12.7 (br. s, OH), 8.28--8.31 (3H, m, H-5, −7, −9), 7.85 (1H, d, *J* = 8.7 Hz, H-4), 7.78--7.82 (2H, m, H-6, −8), 7.45 (1H, d, *J* = 8.7 Hz, H-3), 2.39 (3H, s, [CH~3~]{.ul}CO); EIMS *m/z*: 268.0 \[M\]^+^ C~16~H~12~O~4~ (calcd. 268.0736).

### 2.2.2. 1,10-Dihydroxyanthracene-2-butanoate (3) {#sec0030}

White powder; Yield: 29%; IR (KBr) ν~max~ cm^−1^: 3505 (OH), 1768 (ester), 1610--1420 (aromatic moieties), 1304 (O-C); ^1^H NMR (CDCl~3~, 400 MHz): *δ* = 12.7 (br. s, OH), 8.29--8.31 (3H, m, H-5, −7, −9), 7.85 (1H, d, *J* = 8.4 Hz, H-4), 7.79--7.82 (2H, m, H-6, −8), 7.43 (1H, d, *J* = 8.4 Hz, H-3), 2.32 (2H, t, *J* = 7.6 Hz, [CH~2~]{.ul}CO), 1.61 (2H, m, [CH~2~]{.ul}CH~2~CO), 0.89 (3H, t, *J* = 7.2 Hz, [CH~3~]{.ul}CH~2~); EIMS *m/z*: 296.1 \[M\]^+^ C~18~H~16~O~4~ (calcd. 296.1049).

### 2.2.3. 1-Hydroxyanthracene-2,10-dibutanoate (4) {#sec0035}

Yellow powder; Yield: 19%; IR (KBr) ν~max~ cm^−1^: 3505 (OH), 1769 (ester), 1601--1400 (aromatic moieties), 1290 (O-C); ^1^H NMR (CDCl~3~, 400 MHz): *δ* = 12.7 (br. s, OH), 8.30 (1H, s, H-9), 8.28 (1H, d, *J* = 8.4 Hz, H-4), 8.25(1H, dd, *J* = 6.0, 3.2 Hz, H-5), 8.19 (1H, dd, *J* = 5.4, 3.2 Hz, H-7), 7.75--7.77 (2H, m, H-6, −8), 7.59 (1H, d, *J* = 8.4 Hz, H-3), 2.74 (2H, t, *J* = 7.4 Hz, [CH~2~]{.ul}CO(10)), 2.58 (2H, t, *J* = 7.6 Hz, [CH~2~]{.ul}CO(2)), 1.74--1.91 (4H, m, 2([CH~2~]{.ul}CH~2~CO)), 1.03--1.12 (6H, m, 2([CH~3~]{.ul}CH~2~); C~22~H~22~O~5~; EIMS *m/z*: 366.1 \[M\]^+^ C~22~H~22~O~5~ (calcd. 366.1467).

### 2.2.4. 1-Hydroxyanthracene-2,10-dihexanoate (5) {#sec0040}

Yellow powder; Yield: 38%; IR (KBr) ν~max~ cm^−1^: 3504 (OH), 1765 (ester), 1610--1415 (aromatic moieties), 1302 (O-C); ^1^H NMR (CDCl~3~, 400 MHz): *δ* = 12.7 (br. s, OH), 8.27--8.33 (4H, m, H-4, −5, −7, −9), 7.92 (1H, dd, *J* = 5.4, 3.2 Hz, H-8), 7.85 (1H, m, H-6), 7.44 (1H, d, *J* = 8.0 Hz, H-3), 2.78 (2H, t, *J* = 7.6 Hz, [CH~2~]{.ul}CO(10)), 2.65 (2H, t, *J* = 7.6 Hz, [CH~2~]{.ul}CO(2)), 1.77--1.94 (4H, m, 2([CH~2~]{.ul}CH~2~CO)), 1.31--1.35 (8H, br., 2(([CH~2~)~2~]{.ul}CH~3~)), 0.89 (6H, m, 2([CH~3~]{.ul}CH~2~)); EIMS *m/z*: 422.2 \[M\]^+^ C~26~H~30~O~5~ (calcd. 422.2093).

### 2.2.5. Anthracene-1,2,10-triacetate (6) {#sec0045}

Brownish powder; Yield: IR (KBr) ν~max~ cm^−1^: 33.7%; 1772 (ester), 1609--1420 (aromatic moieties), 1309 (O-C); ^1^H NMR (CDCl~3~, 400 MHz): *δ* = 8.32 (1H, s, H-9), 7.99 (1H, m, H-5), 7.89 (1H, m, H-7), 7.86 (1H, d, *J* = 9.2 Hz, H-4), 7.49--7.52 (2H, m, H-6, −8), 7.34 (1H, d, *J* = 9.2 Hz, H-3), 2.61(3H, s, [CH~3~]{.ul}CO(1)), 2.52 (3H, s, [CH~3~]{.ul}CO(10)), 2.35 (3H, s, [CH~3~]{.ul}CO(2)); EIMS *m/z*: 352.1C~20~H~16~O~6~ \[M\]^+^ (calcd. 352.0947).

### 2.2.6. Anthracene-1,2,10-trihexanoate (7) {#sec0050}

Yellowish powder; Yield: 33.7%; IR (KBr) ν~max~ cm^−1^: 1765 (ester), 1610--1415 (aromatic moieties), 1298 (O-C); ^1^H NMR (CDCl~3~, 400 MHz): *δ* = 8.31 (1H, dd, *J* = 6.0, 3.2 Hz, H-5), 8.29 (1H, s, H-9), 7.95--7.99 (1H, m, H-7), 7.86--7.89 (1H, m, H-6), 7.82 (1H, d, *J* = 9.6 Hz, H-4), 7.79 (1H, dd, *J* = 6.0, 3.2 Hz, H-8), 7.32 (1H, d, *J* = 9.6 Hz, H-3), 2.89 (2H, t, *J* = 7.6 Hz, C*H~2~*CO(1)), 2.78 (2H, t, *J* = 7.6 Hz, [CH~2~]{.ul}CO(10)), 2.58 (2H, t, *J* = 7.6 Hz, [CH~2~]{.ul}CO(2)), 1.75--1.96 (6H, m, 3([CH~2~]{.ul}CH~2~CO)), 1.31--1.35 (12H, br., 3(([CH~2~)~2~]{.ul}CH~3~)), 0.91 (9H, m, 3([CH~3~]{.ul}CH~2~)); EIMS *m/z*: 520.2C~32~H~40~O~6~ \[M\]^+^ (calcd. 520.2825).

### 2.2.7. Anthracene-1,2,10-trioctanoate (8) {#sec0055}

Yellowish powder; Yield: 22.3%; IR (KBr) ν~max~ cm^−1^: 1770 (ester), 1605--1415 (aromatic moieties), 1305 (O-C); ^1^H NMR (CDCl~3~, 400 MHz): *δ* = 8.31 (H, dd, *J* = 5.6, 3.2 Hz, H-5), 8.29 (1H, s, H-9), 7.96--7.99 (1H, m, H-7), 7.86--7.89 (1H, m, H-6), 7.80 (1H, d, *J* = 9.6 Hz, H-4), 7.79 (1H, dd, *J* = 5.6, 3.2 Hz, H-8), 7.32 (1H, d, *J* = 9.6 Hz, H-3), 2.89 (2H, t, *J* = 7.6 Hz, [CH~2~]{.ul}CO(1)), 2.78 (2H, t, *J* = 7.6 Hz, [CH~2~]{.ul}CO(10)), 2.58 (2H, t, *J* = 7.6 Hz, [CH~2~]{.ul}CO(2)), 1.75--1.96 (6H, m, 3([CH~2~]{.ul}CH~2~CO)), 1.31--1.35 (24H, br., 3(([CH~2~)~4~]{.ul}CH~3~)), 0.91 (9H, m, 3([CH~3~]{.ul}CH~2~)); EIMS *m/z*: 604.4C~38~H~52~O~6~ \[M\]^+^ (calcd. 604.3764).

2.3. Anticholinesterase assay {#sec0060}
-----------------------------

Anticholinesterase inhibition activity was determined by Ellman's spectrophotometric method ([@bib0030]) using acetylcholinesterase as substrate and 5,5′-dithio-bis(2-nitrobenzoic) acid (DTNB) as chromogen. Horse butyrylcholinesterase (EC 3.1.1.8) was purchased from Sigma (St. Luios, MO, USA) and prepared by dissolving in phosphate buffer (100 mM, pH 8.0). The BuChE concentration was adjusted to 0.2 U per well. 180 μL of sodium phosphate buffer (pH 8.0) and 10 μL buffered Ellman's Reagent (DTNB, 0.1 M NaHCO~3~) was added in wells labeled as blank (substrate and enzyme), control and test. 10 μL of test compound solution (conc. varies 5--500 μM) was added in each well labeled as test. Then, 20 μL of BuChE solution was added in each well including enzyme, control and test. The contents were mixed and incubated for 15 min at 25 °C. The reaction was then initiated by adding 10 μL of substrate solution butyrylcholinesterase iodide (10 mM) in each well except enzyme. The hydrolysis of acetylthiocholine or butyrylthiocholine was determined by the formation of yellow 5-thio-2-nitrobenzoate anion as a result of the reaction with DTNB with thiocholines, catalyzed by enzymes at a wavelength of 412 nm. Methanol was used as negative control. Inhibition percentage was calculated according to Michaelis--Menten model by using "EZ-Fit. The IC~50~ values were determined by monitoring the inhibition effects of various concentrations of under investigation compounds and calculated EZ-Fit, Enzyme Kinetics Program (Perrella Scientific In., Amhherset, USA).

2.4. *In silico* (docking) analysis {#sec0065}
-----------------------------------

### 2.4.1. Preparation of molecules {#sec0070}

After performing enzyme inhibition analysis, newly synthesized compounds were subjected to *in silico* (docking) studies. For docking studies, 3D structure of receptor BuChE (PDB ID: 1POI) was obtained from PDB (<http://www.rcsb.org>). All ligands and water molecules were deleted, followed by addition of polar hydrogen. Structure of standard eserine (physostigmine, M.F.: C~15~H~21~N~3~O~2~) was obtained from Pubchem (CID 5983) in sdf format that was subsequently converted into mol2 format by using Open Babel GUI (graphical user interface) software ([@bib0085]). *In silico* preparation of anthrarobin derivatives (lead compounds) was accomplished by using Accelrys Discovery Studio Visulaizer V2.5 in sketch mode. Gasteiger atomic partial charges were calculated for receptor and all lead compounds and Dreiding-like force field was applied to prepare the final molecules.

### 2.4.2. Selection of binding cavity {#sec0075}

The BuChE active site gorge comprises of 55 amino acids and is ∼ 200 Å^3^ ([@bib0020]). Earlier studies have highlighted many critical residues including D70, W82, G116, G117, A119, A199, S198, L286, V288, E325, Y332 and H438 ([@bib0020]). Among these, D70 and Y332 are present at peripheral anionic site (PAS) and are crucial for preliminary binding of substrate ([@bib0075]). At the bottom of the 20 Å deep gorge, a catalytic triad of S198, H438 and E325 is located. The substrate specificity for catalysis of larger acyl group is determined by L286 and V288 ([@bib0020]; [@bib0075]; [@bib0060]; [@bib0080]). Recent inhibition studies reported that tacrine derivatives can interact differentially with D70, W82, T120, F278, F329, Y332 and H438 ([@bib0025]; [@bib0070]). Therefore, residues that had been found common in multiple publications were considered as most crucial residues. Structural and physiological details regarding the active site pocket were obtained for the determination of binding site. In order to cover all the possible interactions within the binding pocket, D70, V288 and H438 were selected.

### 2.4.3. Docking analysis {#sec0080}

FlexX ([@bib0100]) was employed for docking purpose in batch mode. Standard (eserine) and lead candidates were docked on BuChE active site gorge using default parameters. The software was allowed to search for an optimal conformation and binding mode of each compound within 10 Å (default) radius of search sphere.

3. Results and discussion {#sec0085}
=========================

3.1. Chemistry {#sec0090}
--------------

The anthrarobin acyl derivatives **2**--**8** ([Fig. 1](#fig0005){ref-type="fig"}) were prepared by reaction of anthrarobin (**1**) and acetic anhydride or acyl chlorides as described in the Experimental Part.Fig. 1Synthetic scheme of the products.Fig. 1

The IR spectra of the products showed the absorption bands in the ranges 1760--1772 and 1400--1610 cm^−1^ for the ester and aromatic moieties, respectively. The IR spectra of **2**--**5** also showed a broad absorption band in the range of 3470--3510 cm^−1^ for the free hydroxyl group. In the ^1^H NMR spectra of the products (supplementary material), anthrarobin skeleton protons resonated in the range of δ 7.32--8.33.The carbonyl attached methyl protons exhibited singlets in the range of δ 2.25--2.38 and methylene protons exhibited triplet in the range of δ 2.32--2.36. The terminal methyl protons showed triplets in the range of δ 0.85--1.13. The first acyl groups were attached to the 2-OH because the lone pair of oxygen was less involved in the resonance. The second acyl groups whether attached with 1-OH or 10-OH, can be confirmed based on the downfield signals of the hydrogen bonded protons in the range of 11.7--12.7. The products **4** and **5** showed downfield signals at δ 11.7--12.5 confirming the second acyl group attached with the 10-OH. EI-MS spectral data also confirmed the number of acyl groups (mono, di or tri) in the products.

3.2. BuChE inhibition activity {#sec0095}
------------------------------

All the products were screened for the BuChE inhibition activity. The products **4** and **5** showed outstanding BuChE inhibition activity while the other products showed non-significant activity ([Table 1](#tbl0005){ref-type="table"}) when compared with the standard eserine. On the basis of structure-activity relationship, it is suggested that the position of the acyl groups may influence the BuChE inhibition activity. The active products have acyl groups at 2-OH and 10-OH position and this specific arrangement may favor to block the active sites of the BuChE enzyme.Table 1IC~50~ values of butyryl cholinesterase inhibition activity of the products.Table 1CompoundsButyrylcholinesterase inhibition activity\
IC~50~ μM ± SEMAnthrarobin (**1**)89.3 ± 0.211,10-Dihydroxyanthracene-2-acetate (**2**)85.2 ± 0.211,10-Dihydroxyanthracene −2-butanoate (**3**)\>2501-Hydroxyanthracene-2,10-dibutanoate (**4**)17.2 ± 0.471-Hydroxyanthracene-2,10-dihexanoate (**5**)5.3 ± 1.23Anthracene-1,2,10-triacetate (**6**)69.2 ± 0.40Anthracene-1,2,10-trihexanoate (**7**)NilAnthracene-1,2,10-trioctanoate (**8**)\>250Eserine7.8 ± 0.27[^1]

3.3. *In silico* studies {#sec0100}
------------------------

### 3.3.1. In silico studies of Eserine {#sec0105}

For eserine, best pose gave an energy score of −15.6376 kcal/mol, in which 6 amino acids (W82, P285, A328, F329, Y332 and H438) showed interactions with ligand. Eserine formed one H-bonds with Pro285. H9 of eserine formed H-bond with O of proline side chain.W82 found to have 4H3C-π interactions 2 with each of C20 and C19 of eserine. H438 also have 2 H~3~C-π interactions, one each with C20 and C19 of serine ([Table 2](#tbl0010){ref-type="table"}). Ring 1 of eserine was found to form 4 π interactions: 1 each with A328, H438 and 2 with F329. Tyr332 showed three hydrophobic interactions with ring 1, C16 and N15-C14 bond pair of eserine. G116 was not directly interacting but seems to be the part of hydrophobic interacting loop ([Fig. 2](#fig0010){ref-type="fig"}).Fig. 2Eserine docked in BuChE binding pocket using FlexX software. Eserine forms H-bonds with P285 of the receptor. Stability as Energy minimization for interacting bond is depicted on bond representative line. Residues shown in green indicate hydrophobic interactions with ligand molecule.Fig. 2Table 2Scores of bonding pattern of three compounds.Table 2Eserine1-Hydroxyanthracene-2,10-dibutanoate (**4**)1-Hydroxyanthracene-2,10-dihexanoate (**5**)W821 (∼5 Å)4 (∼4.43 Å) + 1 (∼4.32 Å)5 (∼3.84 Å)G1161 (∼4 Å)G117F3292 (at 5 Å)3 (∼4.1933 Å)3 (∼4.05 Å) + 1 (∼4.97 Å)H4381 (4.2 Å) + 1 (3.75 Å) + 2 (4.5 Å)2 (∼4.13 Å)2 (∼4.08 Å)

### 3.3.2. In silico studies of 1-Hydroxyanthracene-2,10-dibutanoate (4) {#sec0110}

In the best pose, 11 amino acids of receptor (W82, G115, G116, G117, S198, A199, W231, A328, F329, Y332 and H438) ([Table 2](#tbl0010){ref-type="table"}) interacted with ligand molecule with docking energy of − 23.1159 kcal/mol. O15 on aromatic ring system 2 of compound **4** formed 3H-bonds with α-amino groups of G116, G117 and A199 simultaneously, where the amino group of each amino acid acted as hydrogen bond donor. The hydroxyl group of S198 side chain, acted as an H-bond donor and acceptor for O26 of substituted group attached to C9 and O17 attached to C10 of ring 2, respectively. The sp^2^ hybridized N and aromatic ring of H438 formed a H-bond with O17 (H-bond donor) and 4 horizontally displaced π- π interaction among which, two were with ring 1 and one each with ring 2 and ring 3 ([Fig. 3](#fig0015){ref-type="fig"}).Fig. 31-Hydroxyanthracene-2,10-dibutanoate (**4**) molecule docked in BuChE receptor. The docked conformation shows H-bonding of anthrarobin with G116, G117, S198, A199 and H438. Red lines represent strong interactions while blue lines show weak interaction. Stability as energy minimization (e.m.) for each bond is represented on the bond representative line. Residues shown in green indicate pi or hydrophobic interactions with ligand molecule.Fig. 3

The bond pairs of peptide bonds between G117-G116-G115 found to have 2 π interactions with ring 2 of **4**. There were five H~3~C-π interactions observed between receptor and ligand, among which two were between W231 and C21, one in between A328 and ring 3, one each between C25 and F329, C25 and Y332. The second tryptophan in the pocket, W82 formed 3 displaced π-π interactions with ring 3. Phenyl group of F329 was also found to make 4 horizontal π-π interactions, 2 interactions with each of between aromatic rings1 and 2 of ligand.

### 3.3.3. In silico studies of 1-Hydroxyanthracene-2,10-dihexanoate (5) {#sec0115}

In the best pose, 9 amino acids (W82, G115, G116, G117, S198, A199, A328, F329, and H438) ([Table 2](#tbl0010){ref-type="table"}) were shown to interact with ligand (-18.8779 kcal/mol energy score). Most of the interactions observed between compound **5** and receptor were similar to that of compound **4**, for instance A328, W82, G115-G116 bond pair, G116-G117 bond pair, F329 and H438 behaved with compound **5** similarly as with compound **4**, with the exception that the H438 accepts H-bond from O20 instead of O17 and having an additional T-stacking with ring 3 ([Fig. 4](#fig0020){ref-type="fig"}).Fig. 4The binding pocket of BuChE showing docked conformation of ligand 1-hydroxyanthracene-2,10-dihexanoate (**5**). Conformation shows H-bonds of the ligand with G116, G117 and A199. Red lines represent strong interactions while blue line showing weak interaction. Stability as energy minimization for each bond is represented on the bond representative line. Residues (Green) shown in outline forming other interaction.Fig. 4

Hydrogen bonds of G116, G117 and A199 were also retained with only exception that O19 of compound **5** was involved. Similarly, the interaction behavior of S198 was similar to that of compound **4** with an exception that the interacting atoms of ligand were O33 and O20. W82 also has two H~3~C-π interactions with terminal C31 (terminal methyl) of substituted group attached C4 of Aromatic ring system 1. Here W231 and Y332 were failed to interact with compound **5**, in addition to this they seemed not to remain in close proximity.

Enzyme inhibition assay results indicated 1-hydroxyanthracene-2,10-dihexanoate (**5**) to be more potent butyryl cholinesterase inhibitor as compared to standard. Docking studies suggested stable binding of compound **4** and **5** with butyryl cholinesterase at W82, G115, G116, G117, S198, A199, F329 and H438 position forming a strong enzyme inhibitor complex and refraining substrate from binding with active site. Although wet lab experiments indicated compound **5** to be more potent inhibitor as compared to compound **4**, docking studies revealed comparatively stronger interaction between receptor and compound **4** with lower docking energy. The observed high inhibitory activity of compound **5** might be due to the contribution of stereo-chemical stabilizing effects (in dynamic system) on interactions involved in binding and comparatively stable H-bonding with G115, G116, G117, S198 and hydrophobic binding with W82, which in turn stabilizes the hydrophobic interactions with H438 and F329. H438 is a member of the catalytic triad. Although H438 interact with compound **5** with slightly higher energy as compared to compound **4** but might take the advantage of stable H-bonding ([Table 3](#tbl0015){ref-type="table"}).Table 3Energy minimization (in kcal/mol) pattern of docking studies.Table 3ResidueEserine\
e.m.[\*](#tblfn0005){ref-type="table-fn"}Compound 4\
e.m.Compound 5\
e.m.W82-2.1-1-2.4G115---10.3-14.6G116G117S198---3.9-4.1A199---4.7-4.7P285-4.7----F329-0.5-3.3-2.8H438-2-6.63-6.4[^2]

4. Conclusion {#sec0120}
=============

Newly synthesized anthrarobin acyl derivatives **2**--**8** were obtained through the reaction of anthrarobin (**1**) and acetic anhydride or acyl chlorides. The compounds **5** and **4** showed remarkable BuChE inhibition potential with IC~50~ values 5.34 and 17.2 μM, respectively when compared with the standard eserine. These bioactive constituents may be considered as the potential candidates for drug development to treat Alzheimer's disease. It is suggested to perform further *in-vivo* studies to evaluate the toxicity of compounds in animal models.
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[^1]: Values are expressed as mean of three experiments with standard error of the mean (SEM).

[^2]: e.m. is energy minimization.
